Rani Therapeutics Holdings, Inc. (NASDAQ: RANI)

Rani Therapeutics Holdings, Inc. (RANI), a company operating within the biotherapeutics industry, is dedicated to advancing technologies for the oral administration of biologics and drugs. The company's primary business activities revolve around developing a portfolio of oral therapeutics using its unique and innovative delivery technology, the RaniPill capsule. This technology is designed to deliver a wide range of drug substances, including antibodies, proteins, peptides, and oligonucleotides.

RANI's technology platform is drug-agnostic, meaning it can be used to deliver a variety of biologics and drugs. The company has developed two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is engineered to deliver up to 3 mg of drug in microtablet form with high bioavailability, while the RaniPill HC is designed to enable the delivery of drug payloads up to 200µL in liquid form with high bioavailability.

The company has successfully completed three Phase 1 clinical trials using its RaniPill capsule technology. One of these trials involved RT-111, a RaniPill GO capsule containing an ustekinumab biosimilar, which was developed in collaboration with Celltrion, Inc. The study met all its endpoints, and RT-111 was well tolerated, with no serious adverse events reported.

RANI's product pipeline includes RT-102, a RaniPill capsule containing a novel formulation of parathyroid hormone (PTH) for the treatment of osteoporosis, and RT-105, a RaniPill capsule containing a formulation of adalimumab for the treatment of psoriatic arthritis. The company has entered into a License and Supply Agreement with Celltrion for the development and commercialization of RT-105.

RANI's technology has the potential to revolutionize the way biologics and drugs are administered, offering patients a more convenient and pain-free alternative to injections. The company's competitors in the oral biologics market include Pfizer, Merck, and Johnson & Johnson, who are all developing their own oral biologics programs. However, RANI's proprietary technology and expertise in oral biologics delivery may provide it with a competitive advantage in the market.

Celltrion, Inc., a leading biopharmaceutical company, is one of RANI's customers. The partnership between the two companies provides RANI with access to Celltrion's expertise and resources, as well as its global commercialization capabilities.

In terms of its product line, RANI has a variety of brand names and trade names for its services and products. These include the RaniPill capsule, RT-111, RT-102, and RT-105. The RaniPill capsule is the company's proprietary delivery technology, while RT-111, RT-102, and RT-105 are oral therapeutics in various stages of development.

RANI's strategy includes pursuing validated and commercially established market opportunities, expanding in-house manufacturing of the RaniPill capsule, investing in the RaniPill capsule capabilities, expanding its reach by selectively entering into strategic partnerships, and continuing to strengthen its intellectual property portfolio.

The company's regulatory pathway includes obtaining approval or license to market the RaniPill capsule from the FDA. RANI has completed a pre-IND meeting with the FDA with respect to RT-102, and believes that a 505(b)(2) pathway is suitable for the development of RT-102 in the U.S.

RANI has also entered into License and Supply Agreements with Celltrion for the development and commercialization of RT-111 and RT-105, which provide it with exclusive rights to manufacture, develop, and commercialize the drugs worldwide, subject to certain conditions. The agreements also grant Celltrion an exclusive, worldwide license under certain intellectual property generated in the programs, and provide for mutual indemnification and customary representations, warranties, and covenants.